AR045752A1 - Derivados de quinazolina que poseen actividad antitumoral - Google Patents
Derivados de quinazolina que poseen actividad antitumoralInfo
- Publication number
- AR045752A1 AR045752A1 ARP040103319A ARP040103319A AR045752A1 AR 045752 A1 AR045752 A1 AR 045752A1 AR P040103319 A ARP040103319 A AR P040103319A AR P040103319 A ARP040103319 A AR P040103319A AR 045752 A1 AR045752 A1 AR 045752A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- amino
- group
- alkoxy
- alkylamino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Structural Engineering (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
La presente se refiere a derivados de quinazolina para su uso en la producción de un efecto antiproliferativo que es producido total o por la inhibición de la tirosina quinasa del receptor erbB2 en un animal de sangre caliente tal como el hombre. Reivindicación 1: un derivado de quinazolina caracterizado porque es de la fórmula (1) en donde: R1 se selecciona entre H, hidroxi alcoxi C1-6, cicloalquiloxi C3-7y cicloalquil C3-7-alcoxi C1-6 y en donde los átomos de C contiguos en cualquier cadena alquileno C2-6 dentro de un sustituyente R1 están opcionalmente separados por la inserción en la cadena de un grupo seleccionado entre O, S, SO, SO2, N(R), CO, CON(R3), N(R3)CO, SO2N(R3), y N(R3)SO2, en donde R3 es H o alquilo C1-6; y en donde cualquier grupo CH2 o CH3 dentro de un sustituyente R1 tiene opcionalmente en cada uno de dichos grupos CH2 o CH3 uno o más sustituyentes halógeno o alquilo C1-6, o un sustituyente seleccionado entre hidroxi, ciano, amino, carboxi, carbamoilo, sulfamoilo, oxo, tioxo, alcoxi C1-6, alquiltio C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, alquilamino C1-6, di-[(C1-6)alquil]amino, alcoxicarbonilo C1-6, N-alquilcarbamoilo C1-6. N,N-di-[(C1-6)alquil]carbamoilo, alcanoilo C2-6, alcanoiloxi C2-6, alcanoilamino C2-6, N-alquil C1-6-alcanoilamino C2-6, N-alquilsulfamoilo C1-6, N,N-di[(C1-6)alquil]sulfamoilo, alcansulfonilamino C1-6 y N-alquil C1-6-alcansulfonilamino C1-6, Y se selecciona entre H, halógeno, alquilo C1-4, alcoxi C1-4, alquenilo C2-6 y alquinilo C2-4; a es 0, 1, 2, o 3 o 4; cada R2 que puede ser igual o diferente en cada caso, se selecciona entre halógeno, alquilo C1-4, alcoxi c1-4, alquenilo C2-4 y alquinilo C2-4, X2 es un enlace directo o se selecciona entre O, S, OC(R4)2, SC(R4)2, SO, SO2, N(R4), CO y N(R4)C(R4)2 en donde cada R4 que puede ser igual o diferente en cada caso, se selecciona entre H o alquilo C1-6, y Q2 es arilo o heteroarilo; y en donde Q2 tiene opcionalmente uno o más sustituyentes (por ejemplo 1, 2 o 3) que pueden ser iguales o diferentes, seleccionados entre halógeno, ciano, nitro, hidroxi, amino, carboxi, carbamoilo, sulfamoilo, formilo, mercapto, alquilo C1-6, alquenilo C2-8, alquinilo C2-8, alcoxi C1-6, alqueniloxi C2-6, alquiniloxi C2-6, alquiltio C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, alquilamino C1-6, di-[(C1-6)alquil]amino, alcoxicarbonilo C1-6, N-alquilcarbamoilo C1-6, N,N-di-[(C1-6)alquil]carbamoilo, alcanoilo C2-6, alcanoiloxi C2- 6, alcanoilamino C2-6, N-alquil C1-6-alcanoilamino C2-6, alquenoilamino C3-6, N-alquil C1-6-alquenoilamino C3-6, alquinoilamino C3-6, N-alquil C1-6-alquinoilamino C3-6, N-alquilsulfamoilo C1-6, N,N-di-[(C1-6)alquil]sulfamoilo, alcansulfonilamino C1- 6, N-alquil C1-6-alcansulfonilamino C1-6, y u grupo de la fórmula -X4-R5 en donde X4 es un enlace directo o se selecciona entre O, CO y N(R6), en donde R6 es H o alquilo C1-6, y R5 es halógeno-alquilo C1-6, hidroxi-alquilo C1-6, carboxi-alquilo C1- 6, alcoxi C1-6-alquilo C1-6, ciano-alquilo C1-6, amino-alquilo c1-6, N-alquilamino C1-6-alquilo C1-6, N,N-di[(C1-6) alquil]amino-alquilo C1-6, alcanoilamino C2-6-alquilo C1-6, N-alquil C1-6-alcanoilamino C2-6-alquilo C1-6, alcoxicarbonilamino C1-6- alquilo C1-6, carbamoil-alquilo C1-6, N-alquilcarbamoil C1-6-alquilo C1-6, N,N-di-[(C1-6)alquil]carbamoil-alquilo C1-6, sulfamoil-alquilo C1-6, N-alquilsulfamoil C1-6-alquilo C1-6, N,N-di-alquilsulfamoil C1-6-alquilo C1-6, alcanoil C2-6-alquilo C1- 6, alcanoiloxi C2-6-alquilo C1-6 o alcoxicarbonil C1-6-alquilo C1-6, y en donde cualquier grupo CH2 o CH3 dentro de -X2-Q2 tiene opcionalmente en cada uno de dichos CH2 o CH3 uno o más (por ejemplo 1, 2, o 3) sustituyentes halógeno o alquilo C1-6 o un sustituyente seleccionado entre hidroxi, ciano, amino, alcoxi C1-4, alquilamino C1-4 y di-[(C1-4)alquil]amino; X1 es un enlace directo o C(R7)2 en donde cada R7, que puede ser igual o diferente en cada caso, se selecciona entre H y alquilo C1-4, el anillo Q1 es un grupo heterociclilo saturado o parcialmente insaturado de 4, 5, 6, o 7 miembros que contiene 1 heteroátomo de N y opcionalmente 1 o 2 heteroátomos adicionales seleccionados entre O, S y N, y cuyo anillo está unido al grupo X1 por un C del anillo, X3 es un grupo de la fórmula -(CR8R9)p-(Q3)m(CR10R11)q- en donde m es 0 o 1, p es 0, 1, 2, 3 o 4 y q es 0, 1, 2, 3 o 4, cada uno de R8, R9, R10 y R11, que puede ser igual o diferente en cada caso, se selecciona entre H y alquilo C1- 6, y Q3 se selecciona entre cicloalquileno C3-7 y cicloalquenileno C3-7; Z se selecciona entre hidroxi, amino, alquilamino C1-6, di[(C1-6)alquil]amino, alcoxi C1-6, alquilsulfonilo C1-6, alcansulfonilamino C1-6, N-alquil C1-6-alcansulfonilamino C1- 6, y un grupo de la fórmula Q4-X5- en donde X5 es un enlace directo o se selecciona entre O, N(R12), SO2 y SO2N(R12), en donde R12 es H o alquilo C1-6, y Q4 es cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-4, cicloalquenilo C3-7, cicloalquenil C3-7- alquilo C1-4, heterociclilo o heterociclil-alquilo C1-4, con la salvedad de que cuando X5 es un enlace directo, Q4 es heterociclilo, y con la salvedad de que cuando m, p y q son todos 0, entonces Z es heterociclilo, y en donde los átomos de C contiguos en cualquier cadena alquileno C2-6 dentro de un sustituyente Z están opcionalmente separados por la inserción en la cadena de un grupo seleccionado entre O, S, SO, SO2, N(R13), CO, -C=C- y -C=C- en donde R13 es H o alquilo C1-6, y en donde cualquier grupo CH2 o CH3 dentro de cualquier grupo Z, X1 o X3, a excepción de un grupo CH2 dentro de un anillo heterociclilo, tiene opcionalmente en cada uno de dichos grupos CH2 o CH3 uno o más sustituyentes halógeno o alquilo C1-6 o un sustituyente seleccionado entre hidroxi, ciano, amino, carboxi, carbamoilo, sulfamoilo, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alquiltio C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, alquilamino C1-6, di-[(C1-6)alquil]amino, N- alquilcarbamoilo C1-6, N,N-di-[(C1-6)alquil]carbamoilo, alcanoilo C2-6, alcanoiloxi C2-6, alcanoilamino C2-6, N-alquil C1-6-alcanoilamino C2-6, N-alquilsulfamoilo C1-6, N,N-di-[(C1-6)alquil]sulfamoilo, alcansulfonilamino C1-6 y N-alquil C1-6- alcansulfonilamino C1-6, y en donde cualquier grupo heterociclilo representado por Q1 o dentro de un sustituyente Z tiene opcionalmente uno o más (por ejemplo 1, 2 o 3) sustituyentes, que pueden ser iguales o diferentes, seleccionados entre halógeno, trifluorometilo, ciano, nitro, hidroxi, amino, formilo, mercapto, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alquiltio C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, alquilamino C1-6, di-[(C1-6)alquil]amino, alcanoilo C2- 6, alcanoiloxi C2-6 y entre un grupo de la fórmula -X6-R14 en donde R6 es un enlace directo o se selecciona entre O, CO, SO2 y N(R15), en donde R15 es H o alquilo C1-4, y R14 es halógeno-alquilo C1-4, hidroxi-alquilo C1-4,alcoxi C1-4-alquilo C1-4, ciano-alquilo C1-4, amino-alquilo C1-4, N-alquilamino C1-4-alquilo c1-4 y N,N-di-[(C1-4)alquil]amino-alquilo c1-4, y en donde cualquier grupo heterociclilo representado por Q1 o dentro de un sustituyente Z opcionalmente tiene 1 o 2 sustituyentes oxo o tioxo, o una sal del mismo aceptable para uso farmacéutico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0321648.8A GB0321648D0 (en) | 2003-09-16 | 2003-09-16 | Quinazoline derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
AR045752A1 true AR045752A1 (es) | 2005-11-09 |
Family
ID=29227164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040103319A AR045752A1 (es) | 2003-09-16 | 2004-09-16 | Derivados de quinazolina que poseen actividad antitumoral |
Country Status (17)
Country | Link |
---|---|
US (1) | US20070015743A1 (es) |
EP (1) | EP1664029B1 (es) |
JP (1) | JP2007505874A (es) |
CN (1) | CN1882572A (es) |
AR (1) | AR045752A1 (es) |
AT (1) | ATE450528T1 (es) |
AU (1) | AU2004272351A1 (es) |
BR (1) | BRPI0414486A (es) |
CA (1) | CA2539024A1 (es) |
DE (1) | DE602004024420D1 (es) |
GB (1) | GB0321648D0 (es) |
IL (1) | IL174260A0 (es) |
MX (1) | MXPA06002965A (es) |
NO (1) | NO20061320L (es) |
TW (1) | TW200526628A (es) |
WO (1) | WO2005026152A1 (es) |
ZA (1) | ZA200602189B (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003040108A1 (en) * | 2001-11-03 | 2003-05-15 | Astrazeneca Ab | Quinazoline derivatives as antitumor agents |
GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
GB0309850D0 (en) * | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
JP2007505873A (ja) * | 2003-09-16 | 2007-03-15 | アストラゼネカ アクチボラグ | チロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
EP1664030A1 (en) * | 2003-09-16 | 2006-06-07 | AstraZeneca AB | Quinazoline derivatives |
DK1667991T3 (da) * | 2003-09-16 | 2008-08-18 | Astrazeneca Ab | Quinazolinderivater som tyrosinkinaseinhibitorer |
EP1667996B1 (en) * | 2003-09-16 | 2009-07-22 | Astrazeneca AB | Quinazoline derivatives |
GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
GB0326459D0 (en) * | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
ES2315834T3 (es) * | 2004-02-03 | 2009-04-01 | Astrazeneca Ab | Derivados de quinazolina. |
JP2008501675A (ja) * | 2004-06-04 | 2008-01-24 | アストラゼネカ アクチボラグ | Erbb受容体型チロシンキナーゼとしてのキナゾリン誘導体 |
ATE501148T1 (de) * | 2004-12-14 | 2011-03-15 | Astrazeneca Ab | Pyrazolopyrimidinverbindungen als antitumormittel |
GB0504474D0 (en) * | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
GB0508717D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
GB0508715D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
JP5235662B2 (ja) * | 2005-06-16 | 2013-07-10 | ミリアド ジェネティクス, インコーポレイテッド | 薬学的組成物およびその使用 |
JP2009508918A (ja) * | 2005-09-20 | 2009-03-05 | アストラゼネカ アクチボラグ | 癌治療のためのerbB受容体チロシンキナーゼ阻害剤としての4−(1H−インダゾール−5−イル]アミノ)キナゾリン化合物 |
US20090239861A1 (en) * | 2005-09-20 | 2009-09-24 | Robert Hugh Bradbury | Quinazoline derivatives as anticancer agents |
PT2090575E (pt) | 2005-11-15 | 2011-06-06 | Array Biopharma Inc | Inibidores de erbb |
EP1957499A1 (en) * | 2005-12-02 | 2008-08-20 | AstraZeneca AB | 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors |
WO2007063293A1 (en) * | 2005-12-02 | 2007-06-07 | Astrazeneca Ab | Quinazoleine derivatives used as inhibitors of erbb tyrosine kinase |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
MX2009007610A (es) | 2007-02-06 | 2009-07-24 | Boehringer Ingelheim Int | Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion. |
CA2720989A1 (en) * | 2007-04-10 | 2008-10-16 | Myrexis, Inc. | Methods for treating cancer |
CN101742910A (zh) * | 2007-04-10 | 2010-06-16 | 美瑞德制药公司 | 治疗脑癌的方法 |
WO2008124823A1 (en) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Method of treating melanoma |
EP2144887A4 (en) * | 2007-04-10 | 2012-10-03 | Myrexis Inc | PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER |
WO2008124828A1 (en) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Methods for treating vascular disruption disorders |
SI2245026T1 (sl) | 2008-02-07 | 2012-12-31 | Boehringer Ingelheim International Gmbh | Spirociklični heterocikli, zdravila, ki vsebujejo te spojine, njihova uporaba in postopek za njihovo pripravo |
BRPI0912170A2 (pt) | 2008-05-13 | 2015-10-13 | Astrazeneca Ab | composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente |
WO2010015522A1 (de) | 2008-08-08 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
GB0820819D0 (en) | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
RS56608B1 (sr) | 2011-10-14 | 2018-02-28 | Array Biopharma Inc | Čvrsta disperzija |
WO2013056183A1 (en) | 2011-10-14 | 2013-04-18 | Array Biopharma Inc. | Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions contianing them |
TWI811358B (zh) * | 2018-05-08 | 2023-08-11 | 大陸商迪哲(江蘇)醫藥股份有限公司 | ErbB受體抑制劑 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5538325A (en) * | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
US4335127A (en) * | 1979-01-08 | 1982-06-15 | Janssen Pharmaceutica, N.V. | Piperidinylalkyl quinazoline compounds, composition and method of use |
GB2160201B (en) * | 1984-06-14 | 1988-05-11 | Wyeth John & Brother Ltd | Quinazoline and cinnoline derivatives |
US4921863A (en) * | 1988-02-17 | 1990-05-01 | Eisai Co., Ltd. | Cyclic amine derivatives |
CA1340821C (en) * | 1988-10-06 | 1999-11-16 | Nobuyuki Fukazawa | Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components |
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
BR9702049B1 (pt) * | 1996-01-31 | 2010-08-10 | sistema distribuidor contendo dois compartimentos para a dosagem simultánea de duas composições aquosas. | |
US6004967A (en) * | 1996-09-13 | 1999-12-21 | Sugen, Inc. | Psoriasis treatment with quinazoline compounds |
US5929080A (en) * | 1997-05-06 | 1999-07-27 | American Cyanamid Company | Method of treating polycystic kidney disease |
US6148197A (en) * | 1998-03-06 | 2000-11-14 | Sbc Technology Resources, Inc. | Intelligent roaming system with over the air programming |
US6384223B1 (en) * | 1998-07-30 | 2002-05-07 | American Home Products Corporation | Substituted quinazoline derivatives |
US6297258B1 (en) * | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
JP3751201B2 (ja) * | 1999-02-27 | 2006-03-01 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | チロシンキナーゼにより媒介されるシグナル伝達に関する抑制効果を有する4−アミノ−キナゾリン誘導体及びキノリン誘導体 |
US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
US20020082270A1 (en) * | 2000-08-26 | 2002-06-27 | Frank Himmelsbach | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
US6562319B2 (en) * | 2001-03-12 | 2003-05-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy |
EP1396488A1 (en) * | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
WO2003040108A1 (en) * | 2001-11-03 | 2003-05-15 | Astrazeneca Ab | Quinazoline derivatives as antitumor agents |
GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
TW200813014A (en) * | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
US6924285B2 (en) * | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
GB0309850D0 (en) * | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
WO2005012290A1 (en) * | 2003-07-29 | 2005-02-10 | Astrazeneca Ab | Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors |
GB0317665D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
JP2007505873A (ja) * | 2003-09-16 | 2007-03-15 | アストラゼネカ アクチボラグ | チロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
EP1667996B1 (en) * | 2003-09-16 | 2009-07-22 | Astrazeneca AB | Quinazoline derivatives |
DK1667991T3 (da) * | 2003-09-16 | 2008-08-18 | Astrazeneca Ab | Quinazolinderivater som tyrosinkinaseinhibitorer |
ES2281007T3 (es) * | 2003-09-19 | 2007-09-16 | Astrazeneca Ab | Derivados de quinazolina. |
MXPA06003341A (es) * | 2003-09-25 | 2006-06-08 | Astrazeneca Ab | Derivados de quinazolina. |
GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
GB0326459D0 (en) * | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
ES2315834T3 (es) * | 2004-02-03 | 2009-04-01 | Astrazeneca Ab | Derivados de quinazolina. |
JP2008501675A (ja) * | 2004-06-04 | 2008-01-24 | アストラゼネカ アクチボラグ | Erbb受容体型チロシンキナーゼとしてのキナゾリン誘導体 |
-
2003
- 2003-09-16 GB GBGB0321648.8A patent/GB0321648D0/en not_active Ceased
-
2004
- 2004-09-14 WO PCT/GB2004/003936 patent/WO2005026152A1/en active Application Filing
- 2004-09-14 MX MXPA06002965A patent/MXPA06002965A/es unknown
- 2004-09-14 AT AT04768482T patent/ATE450528T1/de not_active IP Right Cessation
- 2004-09-14 EP EP04768482A patent/EP1664029B1/en active Active
- 2004-09-14 AU AU2004272351A patent/AU2004272351A1/en not_active Abandoned
- 2004-09-14 CN CNA2004800335283A patent/CN1882572A/zh active Pending
- 2004-09-14 DE DE602004024420T patent/DE602004024420D1/de active Active
- 2004-09-14 US US10/572,262 patent/US20070015743A1/en not_active Abandoned
- 2004-09-14 JP JP2006526685A patent/JP2007505874A/ja active Pending
- 2004-09-14 CA CA002539024A patent/CA2539024A1/en not_active Abandoned
- 2004-09-14 BR BRPI0414486-4A patent/BRPI0414486A/pt not_active Application Discontinuation
- 2004-09-16 AR ARP040103319A patent/AR045752A1/es unknown
- 2004-09-16 TW TW093128079A patent/TW200526628A/zh unknown
-
2006
- 2006-03-12 IL IL174260A patent/IL174260A0/en unknown
- 2006-03-15 ZA ZA200602189A patent/ZA200602189B/en unknown
- 2006-03-23 NO NO20061320A patent/NO20061320L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2005026152A1 (en) | 2005-03-24 |
ATE450528T1 (de) | 2009-12-15 |
CN1882572A (zh) | 2006-12-20 |
AU2004272351A1 (en) | 2005-03-24 |
EP1664029A1 (en) | 2006-06-07 |
ZA200602189B (en) | 2007-11-28 |
NO20061320L (no) | 2006-04-26 |
BRPI0414486A (pt) | 2006-11-14 |
DE602004024420D1 (de) | 2010-01-14 |
US20070015743A1 (en) | 2007-01-18 |
JP2007505874A (ja) | 2007-03-15 |
TW200526628A (en) | 2005-08-16 |
IL174260A0 (en) | 2006-08-01 |
CA2539024A1 (en) | 2005-03-24 |
MXPA06002965A (es) | 2006-06-14 |
EP1664029B1 (en) | 2009-12-02 |
GB0321648D0 (en) | 2003-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR045752A1 (es) | Derivados de quinazolina que poseen actividad antitumoral | |
AR047703A1 (es) | Derivados de quinazolina | |
CO5680435A2 (es) | Derivados de quinazolina inhibidores de tirosina quinasa erbb y egb, su procedimiento de sintesis y composiciones farmaceuticas que los contienen | |
AR033560A1 (es) | Derivados de quinazolina, proceso para su preparacion, composicion farmaceutica, y su uso en la fabricacion de un medicamento, | |
AR049294A1 (es) | DERIVADOS DE QUINAZOLINA; INHIBIDORES DE LA TIROSINA QUINASA DEL RECEPTOR ERBB2; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN; MÉTODOS PARA SU PREPARACIoN Y SU USO COMO MEDICAMENTO PARA EL TRATAMIENTO O PREVENCIoN DE TUMORES SoLIDOS. | |
CY1124284T1 (el) | Ενωσεις σπειρο[3η-ινδολο-3,2'-πυρρολιδιν]-2(1η)-ονης και παραγωγα ως αναστολεις mdm2-p53 | |
AR039203A1 (es) | Derivados de quinazolina | |
AR038000A1 (es) | Compuesto derivado de tien[2,3-d]pirimidin-2,4(1h,3h)-diona, composicion farmaceutica, proceso para su preparacion y su uso en la fabricacion de un medicamento | |
AR046308A1 (es) | Derivados amida | |
AR060050A1 (es) | Compuestos moduladores del receptor de s1p y uso de los mismos | |
AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
AR056197A1 (es) | Derivados de 7-metilimidazol[1,2-a]piridin-6-il-8-metil-nonamidas como inhibidores de la renina, composciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de la hipertension arterial | |
RU2403250C2 (ru) | Производные пиперидин-4-иламида и их применение в качестве антагонистов рецептора sst подтипа 5 | |
AR040047A1 (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6 | |
AR049091A1 (es) | Derivados de azepinona fusionada como reguladores del crecimiento de plantas | |
AR035783A1 (es) | Compuesto, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular efectos de los receptores de histamina 3 | |
AR061873A1 (es) | Derivados de pirrolotriazina inhibidores de tirosinquinasas, composiciones farmaceuticas que los contienen utiles para el tratamiento de enfermedades proliferativas. | |
AR045414A1 (es) | Derivados de 2 - piridincarboxamida y composiciones farmaceuticas que las contienen. | |
AR069078A1 (es) | Derivados de piridina y pirazina | |
AR044011A1 (es) | Antagonistas de mchr1 heterociclicos | |
AR077849A2 (es) | Compuestos y composiciones como inhibidores de proteina quinasa | |
AR045754A1 (es) | Derivados de quinazolina | |
AR047063A1 (es) | Heterociclos azabiciclicos como moduladores de receptor canabinoide | |
AR054482A1 (es) | Derivados de azetidinona para el tratamiento de hiperlipidemias | |
AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |